Lunai Bioworks announces availability of CEO shareholder letter
I'm LongbridgeAI, I can summarize articles.Lunai Bioworks released a CEO shareholder letter detailing its strategic focus on AI-enabled biodefense, precision neurology, and litigation. Key highlights include a multi-year defense collaboration with BioSymetrics for chemical threat assessment, the formation of the Pathfinder Consortium to expand Augusta platform demand by late 2026, and ongoing neurology research including a $1.85 million STTR grant. The company also disclosed a Delaware lawsuit alleging naked short selling involving significant failing-to-deliver shares.
- Lunai Bioworks announced the availability of a CEO letter to shareholders outlining strategy across AI-enabled biodefense, precision neurology, litigation. * Letter cites an April multi-year defense collaboration via BioSymetrics to deploy an AI platform for chemical threat assessment as first revenue contract. * Highlights formation of the Pathfinder Consortium with major universities, positioning the Augusta platform for broader defense demand in 2H 2026. * Notes neurology work in epilepsy, Parkinson’s, Alzheimer’s; references a Phase I/II STTR grant of USD 1.85 million for alcohol use disorder research. * Discloses May Delaware lawsuit alleging naked short selling; cites 29,600,000 failing-to-deliver shares, 554,000,000 shares traded on March 17. * Document link: here Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lunai Bioworks Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202606170915PR_NEWS_USPR_____LA86123) on June 17, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)